Gene

CD80

CD80 molecule

Explore in graph →CI-GENE-00040531HGNC:1700 ENSG00000121594 NCBI 941 CIViC Approved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CD80 Overexpression1
Cisplatin + GaliximabCombination	B-Cell Non-Hodgkin Lymphoma	Predictive	D	Supports Sensitivity Response	3	submitted	EID12554 In a preclinical study using 5 CD80-overexpressing Burkitt B-cell lymphoma cell lines (Raji, Daudi, Ramos, DHL4, 2F7), treatment with the anti-CD80 monoclonal antibody galiximab (25–100 µg/mL) inhibit… (full text at CIViC) PMID 22267549 · Martinez-Paniagua et al., 2012 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (2)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved2 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Head and Neck Squamous Cell Carcinoma (Johns Hopkins, Science 2011) hnsc_jhu	Head and Neck Squamous Cell Carcinoma	Ssm

Literature

Linked publications (0)

Data not yet available

No publication linked to this gene yet.